China Gender-affirming Hormone Therapy Study
Conditions: Transgender; Gender Incongruence Interventions: Drug: GAHT for transgender men; Drug: GAHT for transgender women Sponsors: Peking University Third Hospital; Tsinghua University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2022 Category: Research Source Type: clinical trials
First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Condition: Breast Cancer Interventions: Drug: RGT-419B; Drug: RGT-419B in combination with hormonal therapy Sponsor: Regor Pharmaceuticals Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
Condition: High Risk Localized Prostate Cancer Intervention: Sponsor: Johnson & Johnson Pte Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials
First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Condition: Breast Cancer Interventions: Drug: RGT-419B; Drug: RGT-419B in combination with hormonal therapy Sponsor: Regor Pharmaceuticals Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 31, 2022 Category: Research Source Type: clinical trials